Ä¿Ç°£¬ÒÑÓÐÊý°ÙÖÖÖÎÁÆÐÔIgG¿¹Ìå½øÈëÁÙ´²ÊÔÑ飬90¶àÖÖ»ùÓÚ¸ÃͬÖÖÐ͵Ŀ¹Ìå²úÆ·ÒÑ»ñµÃFDAÅú×¼¡£ÊÂʵÉÏ£¬IgMÒ²ÒѾÔÚ¸÷ÖÖ¶¯ÎïÄ£ÐÍ£¬°üÀ¨·ÇÈËÁ鳤ÀදÎïÖб»Ö¤ÊµÊÇÓÐÖÎÁÆЧ¹ûµÄ£¬²¢ÒÑÓÐÊ×ÅúIgMµ¥¿Ë¡¿¹ÌåÒ©Îï½øÈëÁËÁÙ´²ÊÔÑé½×¶Î¡£Ô¼20ÖÖIgM¿¹ÌåÔÚÈËÌåÖнøÐÐÁËÊÔÑ飬°üÀ¨Õë¶Ô¸÷ÖÖ´«È¾²¡¡¢Ö×ÁöºÍ×ÔÉíÃâÒßÐÔ¼²²¡¿¹ÔµÄ´óÊó¡¢Ð¡ÊóºÍÈËÔ´IgM¡£
ͼ1 IgM¿¹ÌåÒ©ÎïµÄÁÙ´²ÊÔÑéÊ·
½ØÖ¹ÏÖÔÚ£¬ÉÐδÓÐÖÎÁÆÐÔIgM¿¹ÌåÒ©Îï»ñÅú¡£ÕâÒ»½á¹û¿ÉÄÜÊÇÓÉÓÚ´ó¶àÊý½øÈëÁÙ´²µÄIgM¿¹ÌåÊÇÌìÈ»À´Ô´£¬Î´¾Àú¹ã·ºµÄÌåϸ°ûÍ»±ä£¬Òò´ËÇ׺ÍÁ¦ºÍÌØÒìÐԽϵ͡£Ò©ÎïÔçÆÚÑо¿ÖÐÖ÷Òª¹Ø×¢Ìض¨µÄÊÊÓ¦Ö¢£¬Èçŧ¶¾Ö¢ºÍŧ¶¾ÐÔÐÝ¿Ë£¬Ò²¿ÉÄÜÏÞÖÆÁËIgM¿¹Ìå»ñµÃÒ©Îï¼à¹ÜÈϿɵĿÉÄÜ¡£
±í1 ÁÙ´²ÊÔÑéÖеÄIgM¿¹ÌåÒ©Îï
| Antibody (Name) | Company | IgM Source | Antigen | Indication | Most Advanced Clinical Development |
|---|---|---|---|---|---|
| Campath-1M | Academic (MRC-RDCT) |
Rat | CD52 | Graft vs. host disease | Phase 2 |
| E5 (Xomen-E5) | XOMA | Mouse | J5 lipid A | Sepsis | Phase 3 |
| HA-1A (Centoxin) | Centocor | Human | J5 lipid A | Sepsis | Phase 3 |
| Fanolesomab-Tc99 (NeutroSpec) |
Palatine | Mouse | CD15 | Appendicitis | Phase 3 |
| IgM cocktail (5) | Cutter/Miles | Human | LPS | Sepsis | Phase 1 |
| Mab 16.88 | Academic (Free University Hospital) |
Human | Colon cancer antigen |
Colorectal cancer | Phase 1 |
| MAB-T88 | Chiron | Human | LPS | Neutropenia | Phase 1 |
| PAT-SC1 | Partridge | Human | CD55 isoform |
Gastric cancer | Phase 1 |
| ABX-CBL | Abgenix | Mouse | CD147 | Graft vs. host disease |
Phase 2/3 |
| L612 | Chugai | Human | Ganglioside GM3 |
Melanoma | Phase 1 |
| MORAb-028 | Morphotek/Eisai | Human | Ganglioside GD2 |
Melanoma | Phase 1 |
| AR-101 | Aridis | Human | LPS | Nosocomial P. a. pneumonia |
Phase 2a |
| mAb216 | Academic (Stanford) |
Human | CDIM | B-lineage ALL | Phase 1 |
| PAT-SM6 | Partridge | Human | GRP78 | Multiple myeloma | Phase 1/2a |
| ARG098 | Argenes | Mouse/Human (chimeric) |
FAS | Rheumatoid arthritis |
Phase 1/2 |
| rHIgM22 | Grant | Human | CNS myelin | Multiple sclerosis/neuronal degeneration |
Phase 1 |
| TOL101 | Tolerates | Mouse | ab TCR | Renal transplant | Phase 2 |
1964Ä꣬Barth¼°ÆäͬÊ·¢±íÁËÊ׸öÑо¿Î´½øÐиÄÔìµÄÈËIgM¿¹ÌåÔÚÈËÌåÖÐÒ©Îï´úл¶¯Á¦Ñ§£¨PK£©µÄÎÄÕ¡£²âÊÔʹÓõÄIgM¿¹Ìå´Ó½¡¿µÈËÌåѪÇåÖд¿»¯£¬Óõâ-131·ÅÉäÐÔ±ê¼Çºó£¬×¢Éäµ½Æ߸öÕý³£³ÉÄêÈËÖС£Ã¿ÌìÊÕ¼¯ÑªÇåÑù±¾²¢ÔÚÙ¤Âí¼ÆÊýÒÇÖнøÐзÖÎö¡£Ñо¿·¢ÏÖ£¬Õý³£ÈËIgMÔÚÈËÌåÖеÄÏû³ý°ëË¥Æڵķ¶Î§Îª3.8ÖÁ6.5Ì죬ƽ¾ùΪ5.1Ìì¡£ÖµµÃ×¢ÒâµÄÊÇ£¬ÈËIgMµÄ°ëË¥ÆÚ±ÈÈËÀàÖÐͨ³£±¨¸æµÄÈËIgG°ëË¥ÆÚ£¨18~21Ì죩µÍ3±¶£¬·´Ó³ÁËIgM¿¹Ìå²»ÓëFcRnÊÜÌå½áºÏµÄÊÂʵ¡£
¸ú¾Ý¼¸ÖÖÖÎÁÆÐÔIgMµ¥¿¹µÄÁÙ´²Ò©´ú¶¯Á¦Ñ§ÊÔÑé½á¹û£¬ÕâЩIgMÔÚÈËÌåÖеİëË¥ÆÚ±ÈBarthµÈÈËËùÃèÊöµÄ°ëË¥Æڶ̡£Ó¦¸Ã×¢ÒâµÄÊÇ£¬ÕâЩʵÑéÖ®¼ä´æÔÚ¼¸¸ö¹Ø¼ü²îÒì¡£Ê×ÏÈ£¬Barth²âÊԵĿ¹ÌåÊÇÕý³£È˵ÄIgM£¬Òò´ËËü²»»áÓëÈËÀ࿹ԽáºÏ£¬¶øËæºó²âÊÔµÄÐí¶àIgMÊÇ»áÓëÈËÀ࿹ԽáºÏµÄ¡£Òò´Ë£¬¾¹ýÁÙ´²²âÊÔµÄIgMÓë±í´ïÕâЩ°Ð±êµÄ×éÖ¯½áºÏºó£¬¿ÉÄÜ»á¸ü¿ìµØ±»Çå³ý¡£Æä´Î£¬Barth²âÊԵIJÄÁÏÊÇ´ÓÈËѪÇåÖзÖÀë³öÀ´µÄ£¬¶ø´ó¶àÊýÆäËûIgMÊÇÔÚСÊó¡¢´óÊó»ò²ÖÊó£¨ÀýÈçCHO£©Ï¸°ûÖвúÉúµÄ¡£IgGµÄÉú²úËÞÖ÷ϸ°ûºÍÅàÑøÌõ¼þµÄ±ä»¯»áµ¼ÖÂÌÇ»ù»¯µÄ±ä»¯£¬IgM¿¹ÌåÒ²ÓÐÀàËƵı仯£¬Òò´ËPKʵÑéµÄ²îÒìÊÇÔÚÔ¤ÁÏÖ®Öеġ£·ÖÎö¼¼Êõ£¨Í¬Î»ËØÓëELISA£©ºÍÊÜÊÔÕßȺÌ壨Õý³£Ó뻼²¡£©Ò²ÊDzîÒìµÄ´Ù³ÉÒòËØ¡£
ÒÑÓÐÕë¶ÔһϵÁÐÊÊÓ¦Ö¢µÄÄö³Ý¶¯Îï»òÈËIgM¿¹ÌåÒ©Îï½øÐÐÁËÁÙ´²ÊÔÑé¡£ÔÚÕâЩÊÔÑéÖУ¬½ü400ÃûÊÜÊÔÕß½ÓÊÜÁ˸ߴï27mg/kgµÄÖÎÁƼÁÁ¿£¬²¢ÇÒûÓб¨¸æÃ÷ÏԵݲȫÎÊÌâ¡£ÖØÒªµÄÊÇ£¬¶ÔÓÚÓÃÈËIgM¿¹ÌåÒ©Îï½øÐеÄÁÙ´²Ñо¿£¬ºÜÉÙ»òδ¹Û²ìµ½ÃâÒß·´Ó¦¡££¨ËùʹÓõÄÃâÒßÔÐԲⶨµÄϸ½Ú¼°ÆäÃô¸ÐÐÔÏà¶ÔÐÔÔÝʱûÓоßÌåÖ¸Ã÷¡££©
¼¸ÖÖÈËIgM¿¹ÌåÔÚÁÙ´²Éϱ»°²È«Ê¹ÓÃÁîÈ˹ÄÎè¡£ÀíÂÛÉÏ£¬IgMµÄ¶à¼ÛÐÔÒý·¢µÄ¿¹Ìå¸ßÇ׺ÏÁ¦¿ÉÄܵ¼ÖÂÒ©ÎïÍѰнáºÏ£¬Òý·¢ÒâÏë²»µ½µÄ¶¾ÐÔ»òÒ©ÎïµÄ¿ìËÙÇå³ý¡£Ò»Ð©°ÐÏòÖ×Áö°Ð±êµÄÌìÈ»·ÖÀëµÄIgM¿¹ÌåÖУ¬¿ÉÄÜ´æÔÚµÍÇ׺ÍÁ¦£¨affinity£©¸ßÇ׺ÏÁ¦£¨avidity£©µÄ½áºÏ£¬Õâ¿ÉÄܵ¼ÖÂÒ©ÎïÍѰС£ÔÚÆù½ñΪֹ±¨¸æµÄÁÙ´²Ñо¿ÖУ¬ÕâÑùµÄµ£ÓDz¢Ã»ÓÐʵ¼Ê·¢Éú¡£ºóÐøÕâЩÎÊÌâÖ»ÄÜͨ¹ý½øÒ»²½¿ª·¢ºÍÁÙ´²ÊÔÑéÆäËûIgM¿¹ÌåºòÑ¡²úÆ·À´½â¾ö¡£
Ëæ׎ðÄê»á¡¤(jinnian½ðÄê»á)¶Ô¸÷¸öµ°°×±í´ïϵͳºÍIgM¿¹ÌåÉú²úÀí½âµÄ²»¶ÏÉîÈ룬δÀ´ÒÔIgMΪÔÐÍ¿ª·¢µÄ¹¤³Ì¿¹Ì壬½«»á±»ÓÃÓÚÖÎÁƸ÷ÖÖÊÊÓ¦Ö¢¡£
IgM¾ßÓÐ10»ò12¸ö¿¹Ô½áºÏλµã£¬Äܹ»ÒÔ¸ßÇ׺ÏÁ¦½áºÏ¿¹Ô°Ð±ê£¬¶ÔÓÚÔÚ°©Ï¸°û»òÆäËû°Ðϸ°ûÉÏÖظ´±í´ïµÄϸ°û±íÃæ°Ð±ê£¬Ã¿¸öIgM·Ö×Ó¿ÉÒÔ¶à´Î²ÎÓ뿹ԽáºÏ¡£´ËÍ⣬IgM½á¹¹µÄÁé»îÐÔ¿ÉÒÔΪÔÚϸ°û±íÃæÉϽáºÏ¶à¸ö°Ð±êÌṩÊʵ±µÄ¼Ü¹¹¡£Òò´Ë£¬IgMÌرðÊʺϰÐÏòÀ§ÄѵĿ¹Ô¡£ÔÚһЩÔçÆÚ»ùÓÚIgMµÄ¿ª·¢¹¤×÷ÖУ¬ÔÚÁÙ´²ÊÔÑéÖÐÆÀ¹ÀÁËÕë¶ÔÖ×Áö¿¹ÔÖÐÌÇÀಿ·Ö»òÌÇÖ¬²¿·ÖµÄ¿¹Ìå¡£ÔÚÕâЩÇé¿öÏ£¬ÏàÓ¦µÄIgG¿¹Ìå¶ÔÌDZíλµÄÇ׺ÍÁ¦¿ÉÄܲ»×ãÒÔÓÐЧ°ÐÏò£¬¶øIgM±íÏÖ³öÊʺÏÉúÎïÖÎÁÆÓÃ;µÄÇ¿½áºÏºÍЧӦ¹¦ÄÜ¡£ËùÑ¡Ö×Áö°ÐµãµÄÁíÒ»¸ö¾ßÓÐÌôÕ½ÐԵij¡¾°ÊÇÆäÔÚÖ×ÁöÉϵĵͱí´ï£¬ÌرðÊÇÖÎÁƵֿ¹ÐÔÖ×Áö¡£»ùÓÚIgMµÄ¸ßÇ׺ÏÁ¦¿¹Ö×ÁöÒ©Îï¿ÉÄܶԵͱí´ï»òÆäËûÀ§Äѵİбê²úÉú¸ü¼ÓÓÐЧµÄ¿¹Ìå¡£
Ðí¶àÔçÆÚIgMÈËÌåÁÙ´²ÊÔÑéÖÐʹÓõÄÊÇÌìÈ»IgM¿¹Ì壬ÕâЩ¿¹Ìåͨ³£´Ó»¼ÕßÌåÄÚ·ÖÀë³öÀ´»ò´ÓСÊóÔÓ½»ÁöÖÐÈËÔ´»¯»ñµÃ¡£Î´À´£¬¹¤³Ì»¯µÄIgM¿¹Ìå´æÔÚמ޴óµÄ¿ÉÄÜ¡£È罫Ç׺ÍÁ¦³ÉÊìºóµÄIgG¿¹Ìå¿É±äÇø¼Þ½Óµ½IgMºã¶¨ÇøÉÏ£¬ÕâÖÖÉè¼Æ½«°ïÖúIgMµÄ½áºÏÇ׺ÍÁ¦ºÍЧӦ¹¦ÄÜÏÔÖøÔö¼Ó¡£³ýÁ˽ṹÓòµÄǶºÏÍ⣬ҲÓÐÑз¢Æ½Ì¨ÊÔͼͨ¹ýIgGµÄ¹¤³Ì¸ÄÔ죬½øÒ»²½ÀûÓÃIgMµÄÁù¾ÛÌå½á¹¹¡£ÀýÈçHexaBody?¿¹Ìåƽ̨ÊÇͨ¹ýÔÚIgGÖØÁ´ÖÐÒýÈëÍ»±ä£¬Ê¹Í»±äºóµÄIgGµ¥ÌåÔÚÌض¨Å¨¶ÈϵÄϸ°û±íÃæÒÔÁù¾ÛÌåµÄÐÎʽ´æÔÚ¡£ÕâÖÖÐÎʽµÄ¿¹ÌåÔÚ±£ÁôADCCµÈЧӦµÄͬʱ£¬¿ÉÒÔ¼¤·¢¸üÇ¿µÄCDCЧӦ£¬×ÛºÏÁËIgGºÍIgMЧӦ¹¦ÄÜÓÅÊÆ£¬ÔÚÖÎÁÆЧ¹ûÉϽÏÆÕͨͬÖÖÐ͸üÓÅ¡£
½ðÄê»á¡¤(jinnian½ðÄê»á)»¹¿ÉÒÔͨ¹ýÔÚIgMÉÏÌí¼Ó¶à¸öÌØÒìÐÔ½áºÏλµãÀ´ÓÅ»¯¿¹ÌåÒ©ÎïÖÎÁƹ¦ÄÜ¡£ÀýÈ磬˫ÌØÒìÐÔIgG¿¹ÌåºÍË«ÌØÒìÐÔIgG¿¹Ìå±äÌå±íÏÖ³ö¼«Ç¿µÄÖ×Áö°ÐÏò×÷Óá£È»¶ø£¬ÕâЩ¿¹ÌåÖ»ÓÐÒ»¸öÓëÖ×Áö¿¹ÔµÄ½áºÏλµã¡£Ë«ÌØÒìÐÔIgM»òÐí¿ÉÒÔÓëÀ§ÄÑ»òº±¼ûµÄÖ×Áö¿¹Ô½¨Á¢·Ç³£¸ßµÄÇ׺ÏÁ¦½áºÏ£¬Ñ¡ÔñÐԵؽáºÏTϸ°ûÒÔʵÏÖÓÐЧµÄÖ×Áöϸ°ûɱÉË¡£ÀýÈ磬һÀཫCD3½áºÏλµãÓëJÁ´ÈÚºÏÀ´²úÉúTϸ°ûЧӦ¹¦ÄܵÄË«ÌØÒìÐÔIgM¿¹Ì壬¸Ã¿¹Ìå°üº¬10¸öTAA½áºÏλµãºÍCD3½áºÏλµã¡£ÕâÖÖ¿¹Ìå½á¹¹µÄÒ»¸ö¹Ø¼üÌØÕ÷ÊÇÄܹ»ÔÚµ¥¸ö¸ß±í´ïϸ°ûϵÖÐÖÆÔìÍêÈ«×é×°µÄË«ÌØÒìÐÔIgM¿¹Ìå¡£
Ëæ×ŶÔIgM¿¹ÌåºÍIgM¿¹Ì幤³ÌµÄÖØйØ×¢£¬IgMƽ̨ºÜ¿ÉÄÜƾ½èÆä¹ÌÓÐÓÅÊÆ£¬²úÉú¸Ä½øµÄÉúÎïÖÎÁÆÖÆÆ·£¬ÓÃÓÚÖÎÁÆδÂú×ãµÄÒ½ÁÆÐèÇó¡£½ðÄê»á¡¤(jinnian½ðÄê»á)Ô¤¼ÆδÀ´¾ßÓÐÔöÇ¿ÊÜÌå½»ÁªµÄIgMµÄ¸ß½×¼Û̬ºÍ¸ßЧµÄË«ÌØÒìÐÔIgMӦΪ¿¹Ì幤³ÌºÍ¿ª·¢¸üÓÐЧµÄÖÎÁÆ·½·¨ÌṩеĻú»á¡£
²Î¿¼ÎÄÏ×
Keyt BA, Baliga R, Sinclair AM, et al. Structure, Function, and Therapeutic Use of IgM Antibodies. Antibodies[J], 2020, 9(4): 53. doi:10.3390/antib9040053
ËÕ¹«Íø°²±¸
ËÕICP±¸ºÅ-1
|